WallStreetZenWallStreetZen

NASDAQ: YMAB
Y Mabs Therapeutics Inc Stock Forecast, Predictions & Price Target

Analyst price target for YMAB

Based on 3 analysts offering 12 month price targets for Y Mabs Therapeutics Inc.
Min Forecast
$21.00+38.8%
Avg Forecast
$24.33+60.83%
Max Forecast
$26.00+71.84%

Should I buy or sell YMAB stock?

Based on 3 analysts offering ratings for Y Mabs Therapeutics Inc.
Strong Buy
Strong Buy
1 analysts 33.33%
Buy
2 analysts 66.67%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their YMAB stock forecasts and price targets.

YMAB stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-03-04
lockedlocked$00.00+00.00%2024-03-04
lockedlocked$00.00+00.00%2024-02-20

1 of 1

Forecast return on equity

Is YMAB forecast to generate an efficient return?
Company
N/A
Industry
N/A
Market
36%

Forecast return on assets

Is YMAB forecast to generate an efficient return on assets?
Company
N/A
Industry
N/A

YMAB revenue forecast

What is YMAB's revenue in the next 3 years based on estimates from 3 analysts?
Avg 1 year Forecast
$96.1M+13.36%
Avg 2 year Forecast
$110.9M+30.72%
Avg 3 year Forecast
$126.1M+48.62%
YMAB's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

YMAB revenue growth forecast

How is YMAB forecast to perform vs Biotechnology companies and vs the US market?
Company
14.09%
Industry
38.03%
Market
10.06%
YMAB's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
YMAB's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

YMAB vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
YMAB$15.13$24.33+60.83%Strong Buy
SVRA$4.81$9.25+92.31%Strong Buy
NRIX$13.59$21.33+56.98%Buy
PHAR$10.00$37.00+270.00%Buy
CGEM$15.66$28.75+83.59%Strong Buy

Y Mabs Therapeutics Stock Forecast FAQ

Is Y Mabs Therapeutics Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 3 Wall Street analysts covering (NASDAQ: YMAB) stock is to Strong Buy YMAB stock.

Out of 3 analysts, 1 (33.33%) are recommending YMAB as a Strong Buy, 2 (66.67%) are recommending YMAB as a Buy, 0 (0%) are recommending YMAB as a Hold, 0 (0%) are recommending YMAB as a Sell, and 0 (0%) are recommending YMAB as a Strong Sell.

If you're new to stock investing, here's how to buy Y Mabs Therapeutics stock.

What is YMAB's revenue growth forecast for 2024-2026?

(NASDAQ: YMAB) Y Mabs Therapeutics's forecast annual revenue growth rate of 14.09% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.03%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.06%.

Y Mabs Therapeutics's revenue in 2024 is $84,819,000.On average, 3 Wall Street analysts forecast YMAB's revenue for 2024 to be $4,209,037,314, with the lowest YMAB revenue forecast at $4,178,962,443, and the highest YMAB revenue forecast at $4,244,759,432. On average, 2 Wall Street analysts forecast YMAB's revenue for 2025 to be $4,853,786,517, with the lowest YMAB revenue forecast at $4,853,611,408, and the highest YMAB revenue forecast at $4,854,005,402.

In 2026, YMAB is forecast to generate $5,518,322,971 in revenue, with the lowest revenue forecast at $5,420,962,689 and the highest revenue forecast at $5,615,727,029.

What is YMAB's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: YMAB) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of N/A.

What is YMAB's Price Target?

According to 3 Wall Street analysts that have issued a 1 year YMAB price target, the average YMAB price target is $24.33, with the highest YMAB stock price forecast at $26.00 and the lowest YMAB stock price forecast at $21.00.

On average, Wall Street analysts predict that Y Mabs Therapeutics's share price could reach $24.33 by Mar 4, 2025. The average Y Mabs Therapeutics stock price prediction forecasts a potential upside of 60.83% from the current YMAB share price of $15.13.

What is YMAB's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: YMAB) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.